HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE

Heterocyclic compounds of general structure of Formula l are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of t...

Full description

Saved in:
Bibliographic Details
Main Authors SHAH, CHANDRAVADAN R, LUU, HIEP, TUCCI, FABIO C, BEATON, GRAHAM, RAVULA, SATHEESH B
Format Patent
LanguageEnglish
French
Published 14.03.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Heterocyclic compounds of general structure of Formula l are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung,and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as dieases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of the compounds include (RS)-3-Cyclopropyl-2-{443-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxyl-propionic acid and (R)-1-(4'-{541-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yll-2-fluoro-biphenyl-4-ylycyclopropanecarboxylic acid. Des composés hétérocycliques de structure générale de formule I sont décrits, qui sont des ligands de récepteur d'acide lysophosphatidique, qui sont utiles dans le traitement des maladies et des conditions dépendantes du récepteur de l'acide lysophosphatidique, y compris sans toutefois s'y limiter les maladies concernant la fibrose, par exemple, du coeur, du rein, du foie et du poumon, et la sclérodermie; les maladies inflammatoires, comme la néphropathie diabétique et la maladie intestinale inflammatoire; les maladies oculaires, comme celles concernant la dégénérescence rétinienne; et les maladies nerveuses, comme le prurit et la douleur. Des exemples non limitatifs des composés comprennent l'acide RS)-3-Cyclopropyl-2-{4-[3-méthyl-4-((R)-1-phényl-éthoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propinique et l'acide (R)-(4'(5[1-(2-Chloro-phényl)-éthoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphényl-4-yl)-cyclopropanecarboxylique.
Bibliography:Application Number: CA20142906931